185 related articles for article (PubMed ID: 27180965)
1. [BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinoma].
Zaleśna I; Hartman ML; Czyż M
Postepy Hig Med Dosw (Online); 2016 May; 70():471-88. PubMed ID: 27180965
[TBL] [Abstract][Full Text] [Related]
2. BRAF as a target for cancer therapy.
Dienstmann R; Tabernero J
Anticancer Agents Med Chem; 2011 Mar; 11(3):285-95. PubMed ID: 21426297
[TBL] [Abstract][Full Text] [Related]
3. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer.
McFadden DG; Vernon A; Santiago PM; Martinez-McFaline R; Bhutkar A; Crowley DM; McMahon M; Sadow PM; Jacks T
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):E1600-9. PubMed ID: 24711431
[TBL] [Abstract][Full Text] [Related]
4. Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations.
Ahronian LG; Sennott EM; Van Allen EM; Wagle N; Kwak EL; Faris JE; Godfrey JT; Nishimura K; Lynch KD; Mermel CH; Lockerman EL; Kalsy A; Gurski JM; Bahl S; Anderka K; Green LM; Lennon NJ; Huynh TG; Mino-Kenudson M; Getz G; Dias-Santagata D; Iafrate AJ; Engelman JA; Garraway LA; Corcoran RB
Cancer Discov; 2015 Apr; 5(4):358-67. PubMed ID: 25673644
[TBL] [Abstract][Full Text] [Related]
5. Acquired Secondary RAS Mutation in BRAF
Cabanillas ME; Dadu R; Iyer P; Wanland KB; Busaidy NL; Ying A; Gule-Monroe M; Wang JR; Zafereo M; Hofmann MC
Thyroid; 2020 Sep; 30(9):1288-1296. PubMed ID: 32216548
[No Abstract] [Full Text] [Related]
6. Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
Dankner M; Rose AAN; Rajkumar S; Siegel PM; Watson IR
Oncogene; 2018 Jun; 37(24):3183-3199. PubMed ID: 29540830
[TBL] [Abstract][Full Text] [Related]
7. BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
Cabanillas ME; Patel A; Danysh BP; Dadu R; Kopetz S; Falchook G
Horm Cancer; 2015 Feb; 6(1):21-36. PubMed ID: 25467940
[TBL] [Abstract][Full Text] [Related]
8. [Progress of anti-tumor study based on BRAF].
Yan GR; Xu ZJ; Wang HY; Zhu WL
Yao Xue Xue Bao; 2012 Dec; 47(12):1567-74. PubMed ID: 23460959
[TBL] [Abstract][Full Text] [Related]
9. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines.
Piscazzi A; Costantino E; Maddalena F; Natalicchio MI; Gerardi AM; Antonetti R; Cignarelli M; Landriscina M
J Clin Endocrinol Metab; 2012 Jun; 97(6):E898-906. PubMed ID: 22442268
[TBL] [Abstract][Full Text] [Related]
10. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAF
Hong SP; Ahn SK
Life Sci; 2017 Aug; 183():37-44. PubMed ID: 28645859
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-3151 inactivates TP53 in BRAF-mutated human malignancies.
Lankenau MA; Patel R; Liyanarachchi S; Maharry SE; Hoag KW; Duggan M; Walker CJ; Markowitz J; Carson WE; Eisfeld AK; de la Chapelle A
Proc Natl Acad Sci U S A; 2015 Dec; 112(49):E6744-51. PubMed ID: 26582795
[TBL] [Abstract][Full Text] [Related]
12. Targeting
Burkart J; Owen D; Shah MH; Abdel-Misih SRZ; Roychowdhury S; Wesolowski R; Haraldsdottir S; Reeser JW; Samorodnitsky E; Smith A; Konda B
J Natl Compr Canc Netw; 2018 Sep; 16(9):1035-1040. PubMed ID: 30181415
[TBL] [Abstract][Full Text] [Related]
13. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
[TBL] [Abstract][Full Text] [Related]
14. HER inhibitor promotes BRAF/MEK inhibitor-induced redifferentiation in papillary thyroid cancer harboring BRAFV600E.
Cheng L; Jin Y; Liu M; Ruan M; Chen L
Oncotarget; 2017 Mar; 8(12):19843-19854. PubMed ID: 28423638
[TBL] [Abstract][Full Text] [Related]
15. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
16. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
[TBL] [Abstract][Full Text] [Related]
17. The Significance of BRAFV600E Mutation in Thyroid Cancer in Terms of Novel Targeted Therapies - Overview of Current Knowledge and Studies.
Iva J; Filip G; Martin B; Pavel Ž; Jan Č
Klin Onkol; 2018; 31(5):339-344. PubMed ID: 30541319
[TBL] [Abstract][Full Text] [Related]
18. BRAF mutations in melanoma and colorectal cancer: a single oncogenic mutation with different tumour phenotypes and clinical implications.
Sclafani F; Gullo G; Sheahan K; Crown J
Crit Rev Oncol Hematol; 2013 Jul; 87(1):55-68. PubMed ID: 23246082
[TBL] [Abstract][Full Text] [Related]
19. PLX8394, a new generation BRAF inhibitor, selectively inhibits BRAF in colonic adenocarcinoma cells and prevents paradoxical MAPK pathway activation.
Tutuka CSA; Andrews MC; Mariadason JM; Ioannidis P; Hudson C; Cebon J; Behren A
Mol Cancer; 2017 Jun; 16(1):112. PubMed ID: 28659148
[TBL] [Abstract][Full Text] [Related]
20. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244.
Ball DW; Jin N; Rosen DM; Dackiw A; Sidransky D; Xing M; Nelkin BD
J Clin Endocrinol Metab; 2007 Dec; 92(12):4712-8. PubMed ID: 17878251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
